In vitro and in vivo activity of zabofloxacin and other fluoroquinolones against MRSA isolates from a University Hospital in Egypt

• Autorzy: Mohamed N.M. , Zakaria A.S. , Edward E.A. , Abdel-Bary A.
• Języki publikacji: EN

Abstrakty

EN

The widespread of infections caused by methicillin-resistant Staphylococcus aureus (MRSA), has necessitated the search for alternative therapies; introduction of new agents being a suggestion. This study compares the in vitro and in vivo activities of zabofloxacin, a novel fluoroquinolone, with moxifloxacin, levofloxacin and ciprofloxacin against clinical isolates of MRSA from patients hospitalized in the Alexandria Main University hospital; a tertiary hospital in Alexandria, Egypt, where zabofloxacin has not been yet introduced. The strains tested showed the highest percentage of susceptibility to zabofloxacin (61.2%) among the tested fluoroquinolones with the most effective MIC₅₀ and MIC₉₀ (0.25 and 2 μg/ml, respectively). Time-kill curve analysis revealed a rapid bactericidal activity of zabofloxacin after 6 h of incubation with a quinolone-resistant isolate and complete killing when tested against a quinolone-sensitive isolate with inhibition of regrowth in both cases. PCR amplification and sequencing of QRDRs in selected strains revealed the following amino acid substitutions: Ser-84→Leu in GyrA, Ser-80→Phe in GrlA and Pro-451→Ser in GrlB. The in vivo studies demonstrated that zabofloxacin possessed the most potent protective effect against systemic infection in mice (ED50: 29.05 mg/kg) with lowest count in the dissected lungs (3.66 log10 CFU/ml).The histopathological examination of lung specimens of mice treated with zabofloxacin displayed least congestion, inflammation, oedema and necrosis with clear alveolar spaces and normal vessels. In conclusion, zabofloxacin was proved to possess high in vitro and in vivoefficacy encompassing its comparators and could be considered as a possible candidate for the treatment of infections caused by MRSA. To our knowledge, this is the first study evaluating the in vitro and in vivo activity of zabofloxacin against Egyptian MRSA clinical isolates.

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2019
• Tom: 68
• Numer: 1
• Opis fizyczny: p.59-69,fig.,ref.

Twórcy

autor

Mohamed N.M.

• Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

autor

Zakaria A.S.

• Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

autor

Edward E.A.

• Department of Microbiology and Immunology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt

autor

Abdel-Bary A.

• Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt

Bibliografia

• Abdel-Maksoud M, El-Shokry M, Ismail G, Hafez S, El-Kholy A, Attia E, Talaat M. Methicillin-Resistant Staphylococcus aureusrecovered from healthcare- and community-associated infections in Egypt. Int J Bacteriol. 2016;2016:1–5. doi:10.1155/2016/5751785 Medline
• Borg MA, de Kraker M, Scicluna E, van de Sande-Bruinsma N, Tiemersma E, Monen J, Grundmann H; ARMed Project Mem-bers and Collaborators. Prevalence of methicillin-resistant Staphy lo coccus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother. 2007; 60(6):1310–1315. doi:10.1093/jac/dkm365 Medline
• CLSI. Methods for determining Bactericidal Activity of Anti-microbial Agents: approved guideline M26-A, 1999. Wayne (USA): Clinical and Laboratory Standards Institute.
• CLSI. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard-Ninth Edition M07-A9. 2012. Wayne (USA): Clinical and Laboratory Standards Institute.
• CLSI. Performance standards for antimicrobial susceptibility testing. CLSI approved standard M100-S23. 2013. Wayne (USA): Clinical and Laboratory Standards Institute.
• Dubin PJ, Kolls JK. IL-23 mediates inflammatory responses to mucoid Pseudomonas aeruginosa lung infection in mice. Am J Phy-siol Lung Cell Mol Physiol. 2007;292(2):L519–L528. doi:10.1152/ajplung.00312.2006 Medline
• Falagas ME, Karageorgopoulos DE, Leptidis J, Korbila IP. MRSA in Africa: filling the global map of antimicrobial resistance. PLoS One. 2013;8(7):e68024.doi:10.1371/journal.pone.0068024 Medline
• Fernandes P, Martens E. Antibiotics in late clinical development. Biochem Pharmacol. 2017;133:152–163.doi:10.1016/j.bcp.2016.09.025 Medline
• Hannachi-M’Zali F, Ambler JE, Taylor CF, Hawkey PM. Examination of single and multiple mutations involved in resistance to quinolones in Staphylococcus aureus by a combination of PCR and denaturing high-performance liquid chromatography (DHPLC).J Antimicrob Chemother. 2002;50(5):649–655.doi:10.1093/jac/dkf243 Medline
• Kaatz GW, Moudgal VV, Seo SM. Identification and characteri-za tion of a novel efflux-related multidrug resistance phenotype in Staphylococcus aureus. J Antimicrob Chemother. 2002;50(6):833–838.doi:10.1093/jac/dkf224 Medline
• Karpiuk I, Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. Przegl Epidemiol. 2013;67(3):455–460. Medline
• Kocsis B, Domokos J, Szabo D. Chemical structure and pharmaco-kinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin. Ann ClinMicrobiol Antimicrob. 2016;15(1):34. doi:10.1186/s12941-016-0150-4 Medline
• Kocsis B, Szabo D. Zabofloxacin for chronic bronchitis. Drugs Today (Barc). 2016;52(9):495–500.doi:10.1358/dot.2016.52.9.2530595 Medline
• Kwon AR, Min YH, Ryu JM, Choi DR, Shim MJ, Choi EC.In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. J Antimicrob Chemother. 2006;58(3):684–688.doi:10.1093/jac/dkl304 Medline
• Pan XS, Ambler J, Mehtar S, Fisher LM. Involvement of topoiso-merase IV and DNA gyrase as ciprofloxacin targets in Strepto-coccus pneumoniae. Antimicrob Agents Chemother. 1996;40(10):2321–2326. doi:10.1128/AAC.40.10.2321 Medline
• Park HS, Jung SJ, Kwak JH, Choi DR, Choi EC. DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. Int J Antimicrob Agents. 2010;36(1):97–98.doi:10.1016/j.ijantimicag.2010.02.022 Medline
• Park HS, Kim HJ, Seol MJ, Choi DR, Choi EC, Kwak JH.In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone. Antimicrob Agents Chemother. 2006;50(6):2261–2264. doi:10.1128/AAC.01407-05 Medline
• Park HS, Oh SH, Kim HS, Choi DR, Kwak JH. Antimicrobial activity of zabofloxacin against clinically isolated Streptococcus pneumoniae. Molecules. 2016;21(11):1562.doi:10.3390/molecules21111562 Medline
• Randhawa MA. Calculation of LD50 values from the method of Miller and Tainter, 1944. J Ayub Med Coll Abbottabad. 2009;21(3):184–185. Medline
• Sadaka SM, El-Ghazzawy EF, Harfoush RA, Meheissen M. Evalua -tion of different methods for the rapid diagnosis of methi cillin-resis-tance in Staphylococcus aureus. Afr J Microbiol Res. 2009; 3:49–55.
• Sierra JM, Marco F, Ruiz J, Jiménez de Anta MT, Vila J. Correlation between the activity of different fluoroquinolones and the presence of mechanisms of quinolone resistance in epidemiologically related and unrelated strains of methicillin-susceptible and -resistant Staphylococcus aureus. Clin Microbiol Infect. 2002;8(12):781–790. doi:10.1046/j.1469-0691.2002.00400.x Medline
• Tokajian S. New epidemiology of Staphylococcus aureus infections in the Middle East. Clin Microbiol Infect. 2014;20(7):624–628. doi:10.1111/1469-0691.12691 Medline
• Vidaillac C, Guillon J, Arpin C, Forfar-Bares I, Ba BB, Grellet J, Moreau S, Caignard DH, Jarry C, Quentin C. Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51(3):831–838.doi:10.1128/AAC.01306-05 Medline
• Yun HJ, Min YH, Jo YW, Shim MJ, Choi EC. Increased antibac-terial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV. Int J Antimicrob Agents. 2005; 25(4):334–337. doi:10.1016/j.ijantimicag.2004.11.013 Medline

Identyfikatory

DOI

10.21307/pjm-2019-007